Home › NDC Lookup › Ingredients › Carboxymethylcellulose Sodium, Glycerin,... › 00023-3988-05
Refresh Optive Mega-3 PF carboxymethylcellulose sodium, Glycerin, Polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops — NDC 00023-3988-05 package photo

Refresh Optive Mega-3 PF carboxymethylcellulose sodium, Glycerin, Polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops

by Allergan, Inc. · 1 VIAL in 1 CARTON (0023-3988-05) / 10 mL in 1 VIAL
NDC 00023-3988-05
🏷️ FDA NDC (as labeled) 0023-3988-05 billing pads the labeler segment with a zero
This package
Contains10 mL in 1 vial Pack sizes2 compare ↓
Also comes in: 10 mL 00023-3988-10
OTC On market Non-controlled
🗂️ Data synced Sep 17, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

🆔 Identity & classification

FDA NDC (as labeled) 0023-3988-05
Product NDC 0023-3988
11-digit billing NDC 00023398805
UNII K679OBS311, PDC6A3C0OX, 6OZP39ZG8H
Application # M018
SPL Set ID 326cb5d6-c784-404f-9a13-6d69262dda6e
Established class (EPC) Non-Standardized Chemical Allergen
Physiologic effect Increased Histamine Release; Cell-mediated Immunity; Increased IgG Production
Chemical class Allergens; Glycerol
DEA schedule Non-controlled
Marketing category OTC MONOGRAPH DRUG
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2026-03-01
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance CARBOXYMETHYLCELLULOSE SODIUM; GLYCERIN; POLYSORBATE 80
GCN Seq No 088675
GCN 58818
HICL code 040248
Ingredient (HICL) Carboxymethyl/Gly/Poly80/Pf
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6T
Therapeutic class — specific (HIC3) Artificial Tears
AHFS code 52:92.00.00
AHFS class Eent Drugs, Miscellaneous
FDB label name REFRESH OPTIVE MEGA-3 PF DROPS
FDB brand name Refresh Optive Mega-3 Pf
Legend status O — Over-the-counter (OTC) drug or device
Why two NDCs? The FDA registers this code as 0023-3988-05 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00023-3988-05. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerAllergan, Inc.
FDA applicationM018 (OTC MONOGRAPH DRUG)
Labeler code00023
First marketedMar 2026
Product typeHuman Otc Drug
Portfolio188 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name REFRESH OPTIVE MEGA-3 PF DROPS Ingredient Carboxymethyl/Gly/Poly80/Pf
🧪 What is this product?

Refresh Optive Mega-3 is an over-the-counter eye drop solution marketed under FDA's OTC monograph rules for ophthalmic lubricants. It contains carboxymethylcellulose sodium and glycerin, which are lubricating agents typically used to coat and moisten the eye surface. The product also includes polysorbate 80, an ingredient commonly found in eye drop formulations to help distribute the lubricating components evenly across the eye.

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII R57ZHV85D4
    Boric acid is a weak acid derived from boron. In medicines, it typically serves as a buffer to help maintain the product's pH level and may act as a preservative in certain formulations.
  • UNII 1P9D0Z171K
    BHT is a synthetic antioxidant that prevents fats and oils in medicines from breaking down and becoming rancid. It helps keep the product stable and effective during storage.
  • UNII 71DD5V995L
    A synthetic polymer derived from acrylic acid, crosslinked to form a gel-like substance. It thickens formulations, improves texture, and helps distribute active ingredients evenly in topical products like creams and gels.
  • UNII D5340Y2I9G
    Castor oil is a natural plant-based oil used in medicines as a lubricant, laxative agent, and solvent. It helps medicine ingredients dissolve or flow smoothly and can aid bowel movement in formulations designed for that purpose.
  • UNII RA96B954X6
    Erythritol is a sugar alcohol derived from fermented fruits or grains. It's used as a sweetener and bulking agent in medicines to improve taste without adding significant calories.
  • UNII 0G389FZZ9M
    Levocarnitine is an amino acid derivative that helps transport fatty acids in cells. In medications, it serves as an active nutritional component rather than a typical inactive binder or filler.
  • UNII 84XB4DV00W
    Linseed oil is a plant-based oil extracted from flax seeds. It's used in medicines as an emollient and lubricant to improve texture and help with ingredient mixing in formulations.
  • UNII 13A4J4NH9I
    A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
  • UNII B8WCK70T7I
    Trehalose is a natural sugar made from two glucose molecules linked together. It's used in medicines as a filler to add bulk, a sweetener for taste, and a stabilizer to help keep active ingredients effective during storage.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

10 inactive ingredients listed in the exact product block matched to this NDC.

The official label also statesBoric acid; butylated hydroxyl toluene; carbomer copolymer type A; castor oil; erythritol; flaxseed oil; levocarnitine; polyoxyl 40 stearate; purified water; and trehalose. May contain hydrochloric acid and/or sodium hydroxide (to adjust pH).

Label-section wording can be broader than the structured product block and may mention additional formulation ingredients.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 10 mL
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Refresh Optive Mega-3 PF 5 mg/mL; 10 mg/mL; 80 5 mg/mLthis 00023-3988-05 Allergan, 1 vial — — FDA listed —
REFRESH Optive Mega-3 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-4230-70 Allergan, 70 vials — — FDA listed —
REFRESH OPTIVE Advanced 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-4307-02 Allergan, 1 bottle — — FDA listed —
REFRESH OPTIVE Advanced 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-4491-05 Allergan, 5 vials — — FDA listed —
REFRESH Optive Mega-3 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-5773-05 Allergan, 5 vials — — FDA listed —
Refresh Digital 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-6952-02 Allergan, 1 bottle — — FDA listed —
Refresh Digital PF 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-6954-05 Allergan, 1 vial — — FDA listed —
REFRESH Optive Mega-3 5 mg/mL; 10 mg/mL; 80 5 mg/mL 00023-7151-60 Allergan, 60 vials — — FDA listed —
Droptics Dry Eye Relief .5 g/100mL; 1 g/100mL; 80 .5 g/100mL 85211-0002-01 Droptics 1 bottle — — FDA listed —
About this product: other versions of the same ingredient, strength and form are listed above, least expensive first, with FDA equivalence ratings where available.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

⏳ Availability & generic status

🏛️
2026
On the market since
Mar 2026
📍
2026
Currently FDA-listed
listed with the FDA
🔒
·
No generic listed yet
brand only
ℹ️No FDA-approved generic found

We did not find an FDA-approved generic match for this exact strength, form and route.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Refresh Optive Mega-3 PF (this brand).

Top reported reactions

Macular Degeneration1
Product Container Issue1
Visual Impairment1

Reporter sex

0 reports
Reports over time (by year) — tap or hover for the count & year
2025 2026 1 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
00023-3988-05 You're viewing this 1 VIAL in 1 CARTON (0023-3988-05) / 10 mL in 1 VIAL 2026-03-01 Active
00023-3988-10 1 VIAL in 1 CARTON (0023-3988-10) / 10 mL in 1 VIAL 2026-03-01 Active

Pack size FAQ

What quantity is in NDC 00023-3988-05?
NDC 00023-3988-05 is listed by the FDA — 1 vial in 1 carton / 10 ml in 1 vial.
What NDC number is used to bill for this package of Refresh Optive Mega-3 PF carboxymethylcellulose sodium, Glycerin, Polysorbate 80 5 mg/mL; 10 mg/mL; 80 5 mg/mL Solution/ Drops?
Bill NDC 00023-3988-05 — the 11-digit billing format is 00023398805. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

🧭 About this NDC listing & data coverage

Over-the-counter (OTC) product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Is this NDC FDA-approved?
An NDC listing does not by itself establish FDA approval — the NDC Directory records that a product is listed with FDA, not that it was reviewed and approved. This listing's marketing category is "Otc Monograph Drug". Products approved under an application carry an NDA, ANDA, or BLA number.
Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The FDA registers it as 0023-3988-05, which is what is printed on the packaging and shown on DailyMed. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero: 00023-3988-05, written without dashes as 00023398805. The Identity section at the top of this page lists every form of this code.
What do the three segments of this NDC mean?
In 00023-3988-05, the first segment (00023) is the labeler code FDA assigned to Allergan, Inc.; the middle segment (3988) identifies this specific product — its ingredient, strength, and dosage form; and the last segment (05) identifies this exact package size and type. Together they name one specific package of one specific product.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Allergan, Inc.. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 1 vial (00023-3988-10). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Allergan, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as an over-the-counter product, so it does not require a prescription. Follow the package directions, and ask your pharmacist if you are unsure whether it is right for you.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.

📄 FDA label — Drug Facts FDA SPL

The complete FDA label for this product — the official Drug Facts labeling, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⚠️ Warnings 🧪 Active Ingredient 🧪 Inactive Ingredients 🎯 Purpose
🎯 Indications and Usage 31 words ▾

Uses For the temporary relief of burning, irritation, and discomfort due to dryness of the eye or exposure to wind or sun. May be used as a protectant against further irritation.

⏱️ Dosage and Administration 25 words ▾

Directions Prior to first use, please read the “Instructions for Use” inside this carton. Instill 1 or 2 drops in the affected eye(s) as needed.

⚠️ Warnings 79 words ▾

Warnings For external use only. To avoid contamination, do not touch tip of container to any surface. Replace cap after using. If solution changes color, do not use. Stop use and ask doctor if you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours. Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center right away.

🧪 Active Ingredient 10 words ▾

Active ingredients Carboxymethylcellulose sodium 0.5% Glycerin 1% Polysorbate 80 0.5%

🧪 Inactive Ingredients 34 words ▾

Inactive ingredients Boric acid; butylated hydroxyl toluene; carbomer copolymer type A; castor oil; erythritol; flaxseed oil; levocarnitine; polyoxyl 40 stearate; purified water; and trehalose. May contain hydrochloric acid and/or sodium hydroxide (to adjust pH).

🎯 Purpose 7 words ▾

Purpose Eye lubricant Eye lubricant Eye lubricant

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
← 00023-3921-02 · Allergan, 00023-4230-70 · Allergan, →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.